ArticleBiopolymers2026
Comprehensive Characterization of Solution-Cast Polycaprolactone/MXene/Gelatin Composite Films for Biomedical Applications.
Article in Biopolymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Despite significant advances in the development of biocompatible platforms, such as scaffolds, films, and hydrogels, a challenge remains in formulating films with the right balance of mechanical properties and bioactivity. Herein, we developed biocompatible composite films based on polycaprolactone (PCL), MXene, and gelatin that can be utilized for biomedical applications. PCL and gelatin (from bovine, fish, and porcine skin) were used to design the biocompatible matrix, while MXenes were used as a filler to enhance the mechanical and biological properties of the films. We investigated the influence of these three types of gelatin on the chemical structure, morphology, physicochemical properties, cytotoxicity, biocompatibility, and cell growth. All the films exhibited high tensile strength, ranging from 5 to 10 MPa. The incorporation of a relatively small content of MXene (0.5 wt%) altered the tensile properties of the films with the lower gelatin contents (12-15 wt%). SAXS analysis revealed that the nanometer-scale lamellar stack structures characteristic of PCL, consisting of alternating crystalline and amorphous lamellae, were present in all samples and exhibited a morphology identical to that of neat PCL. In contrast, WAXS showed that the relative intensities of individual PCL reflections varied with sample composition, indicating a preferential orientation of PCL crystallites-and consequently of the lamellar stacks-particularly, in MXene-containing samples. The SEM/SE micrographs displayed a coarse morphology of gelatin nanoparticles in the PCL matrix, and the structure coarseness decreased in the following order: PCL/MX/fish gelatin > PCL/MX/bovine gelatin > PCL/MX/porcine gelatin. In vitro, cell culture experiments with SAOS-2 cells revealed that cell confluence was relatively high on samples with the 14.5 wt% porcine gelatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.